PREMIO endokannabinoid (Levagen®+)

Levagen+ and acute menstrual pain: Effect of Levagen+ (PEA) compared to a placebo on acute menstrual pain in an adult population – a double-blind, randomised, placebo controlled, cross-over clinical trial (manuscript in preparation, Amanda Rao et al., 2024)

Levagen+ and Cognitive Function and BDNF: Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults (RDBPC trial), Nutrients, Kim et al.,2024.

Levagen+ and Skeletal Muscle Hypertrophy, Strength, and Power in Response to Resistance Training: The Effect of Palmitoylethanolamide (PEA) on Skeletal Muscle Hypertrophy, Strength, and Power in Response to Resistance Training in Healthy Active Adults: A Double-Blind Randomized Control Trial, Sport medicine, Huschtscha et al.,2024

Levagen+ and Allergic Rhinitis: The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis- A Double-Blind Placebo-Controlled Trial, Nutrients, Briskey et al., 2023.

Levagen+ and diabetic-related peripheral neuropathic pain: A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology, Pickering et al.,2022.

Levagen+ and Headache Pain: Efficacy of Palmitoylethanolamide (Levagen+TM) Compared to Ibuprofen for Reducing Severity and Duration in Healthy Adults: A Double-Blind, Parallel, Randomized Clinical Trial. Food and Nutrition Sciences, Briskey et al., 2022.

Levagen+ and incidence and symptoms of Upper Respiratory Tract Infection (DBRPC Trial): The Efficacy of Palmitoyl-ethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection—A Double Blind, Randomised, Placebo-Controlled Trial. Nutrients, Rao, et al., 2023.

Levagen+ and migraine pain: Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants—A Double-Blind Randomised Controlled Study. Pharmaceuticals, 17, 145, Briskey et al., 2024.

PK study - Levagen®+: Increased absorption of Palmitoylethanolamide using a novel dispersion technology system (LipiSperse®). Nutriceuticals Food Sci, Briskey et al., 2020.

Clinical Trial – Exercise study Levagen®+: The effect of orally dosed Levagen®+ (palmitoylethanolamide) on exercise recovery in healthy males. Nutrients, Mallard et al., 2020.

Clinical Trial – Join pain Levagen®+: The effect of a dispersible palmitoylethanolamide Levagen®+ compared to a placebo for reducing joint pain in an adult population. Inflammopharmacology, Steels et al., 2019.

Sleep study - Levagen®+: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study, Sleep Sci Pract, Rao et al, 2021.

Joint/Knee Pain Study - Levagen®+: A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Steels et al., 2019.

Lifetime Management - Levagen®+ : Palmitoylethanolamide: A natural compound for health management. Int J Mol Sci, Clayton et al., 2021.

Covid Study - Levagen®+ : Effects of palmitoylethanolamide on proinflammatory markers in adults recently diagnosed with COVID-19. Current Developments in Nutrition, Fessler et al., 2022.

A systematic review and preliminary metaanalysis of preclinical and clinical evidence. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence, Front Psychiatry, Colizzi et al.,2022.

Treatment of Chronic Pain and PEA: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients, Lang-Illievich et al., 2023.